1
|
Zhi Y, Ji H, Pan J, He P, Zhou X, Zhang H, Zhou Z, Chen Z. Downregulated XPA promotes carcinogenesis of bladder cancer via impairment of DNA repair. Tumour Biol 2017; 39:1010428317691679. [PMID: 28222669 DOI: 10.1177/1010428317691679] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Bladder cancer is the most common malignant tumor of urinary system, largely resulting from failure of repair of DNA damage to the environmental insults. The function of XPA in nucleotide excision repair pathway has been well documented. However, participation of XPA in the repair of DNA double-strand break remains unknown. Here, we reported that bladder cancer expressed low XPA levels compared to adjacent non-tumor bladder tissue, and this phenotype was closely associated with chromosomal aberrations. Moreover, downregulated XPA appeared to increase incidence of chromosome aberration. XPA reduction increased cell viability of a bladder cancer cell line RT4, while XPA re-expression decreased the cell viability of RT4 cells. Since high mutation frequency is the basis of mutations of oncogenes and anti-oncogenes, and may be the essence of bladder cancer susceptibility, our study suggests that downregulated XPA may promote carcinogenesis of bladder cancer via impairment of DNA repair.
Collapse
Affiliation(s)
- Yi Zhi
- Urology Institute of People Liberation Army, Southwest Hospital, Third Military Medical University, Chongqing, China
| | - Huixiang Ji
- Urology Institute of People Liberation Army, Southwest Hospital, Third Military Medical University, Chongqing, China
| | - Jinhong Pan
- Urology Institute of People Liberation Army, Southwest Hospital, Third Military Medical University, Chongqing, China
| | - Peng He
- Urology Institute of People Liberation Army, Southwest Hospital, Third Military Medical University, Chongqing, China
| | - Xiaozhou Zhou
- Urology Institute of People Liberation Army, Southwest Hospital, Third Military Medical University, Chongqing, China
| | - Heng Zhang
- Urology Institute of People Liberation Army, Southwest Hospital, Third Military Medical University, Chongqing, China
| | - Zhansong Zhou
- Urology Institute of People Liberation Army, Southwest Hospital, Third Military Medical University, Chongqing, China
| | - Zhiwen Chen
- Urology Institute of People Liberation Army, Southwest Hospital, Third Military Medical University, Chongqing, China
| |
Collapse
|
2
|
Gusella M, Giacopuzzi S, Bertolaso L, Zanoni A, Pezzolo E, Modena Y, Menon D, Paganin P, Weindelmayer J, Crepaldi G, De Manzoni G, Pasini F. Genetic prediction of long-term survival after neoadjuvant chemoradiation in locally advanced esophageal cancer. THE PHARMACOGENOMICS JOURNAL 2016; 17:252-257. [PMID: 26927287 DOI: 10.1038/tpj.2016.9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Revised: 11/12/2015] [Accepted: 12/23/2015] [Indexed: 12/26/2022]
Abstract
Candidate genes involved in DNA repair, 5-fluorouracil metabolism and drug detoxification were genotyped in 124 patients receiving neoadjuvant chemoradiation treatment for locally advanced esophageal cancer and their predictive role for long-term relapse-free survival (RFS) and cancer-specific survival (CSS) were evaluated. A panel including MTHFR 677TT, MDR1 2677GT, GSTP1 114CC, XPC 499CC and XPC 939AC+CC, defined as high-risk genotypes, discriminated subgroups with significantly different outcomes. When the panel was combined with histology, patients split into two subsets with 5-year RFS and CSS rates of 65% vs 27% (hazard ratio (HR) 3.0, P<0.0001) and 69% vs 31% (HR 2.9, P<0.0001), respectively. Combining the 5-single-nucleotide polymorphism (5-SNP) panel with pathological response defined two major informative risk classes with 5-year PFS and CSS rates of 79.4% vs 17.7% (HR 6.71, P<0.0001) and 79.3% vs 26.3% (HR 6.25, P<0.0001), respectively. This classification achieved a sensitivity of 79%, a specificity of 85.4% and an accuracy of 81.8%.
Collapse
Affiliation(s)
- M Gusella
- Department of Oncology, Laboratory of Pharmacology and Molecular Biology, Azienda ULSS 18-Rovigo, Rovigo, Italy
| | - S Giacopuzzi
- Upper Gastrointestinal Surgery Division, University of Verona, Verona, Italy
| | - L Bertolaso
- Department of Oncology, Laboratory of Pharmacology and Molecular Biology, Azienda ULSS 18-Rovigo, Rovigo, Italy
| | - A Zanoni
- Upper Gastrointestinal Surgery Division, University of Verona, Verona, Italy
| | - E Pezzolo
- Department of Oncology, Laboratory of Pharmacology and Molecular Biology, Azienda ULSS 18-Rovigo, Rovigo, Italy.,Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
| | - Y Modena
- Department of Oncology, Unit of Medical Oncology, Azienda ULSS 18-Rovigo, Rovigo, Italy
| | - D Menon
- Department of Oncology, Unit of Medical Oncology, Azienda ULSS 18-Rovigo, Rovigo, Italy
| | - P Paganin
- Department of Oncology, Laboratory of Pharmacology and Molecular Biology, Azienda ULSS 18-Rovigo, Rovigo, Italy
| | - J Weindelmayer
- Upper Gastrointestinal Surgery Division, University of Verona, Verona, Italy
| | - G Crepaldi
- Department of Oncology, Unit of Medical Oncology, Azienda ULSS 18-Rovigo, Rovigo, Italy
| | - G De Manzoni
- Upper Gastrointestinal Surgery Division, University of Verona, Verona, Italy
| | - F Pasini
- Department of Oncology, Unit of Medical Oncology, Azienda ULSS 18-Rovigo, Rovigo, Italy
| |
Collapse
|